• FDA approves new kind of treatment for hairy cell leukemia worldpharmanews
    September 14, 2018
    The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemi
PharmaSources Customer Service